Today: 10 June 2026
UOB stock nudges higher after fresh buyback; US CPI and Fed loom
13 January 2026
1 min read

UOB stock nudges higher after fresh buyback; US CPI and Fed loom

Singapore, Jan 13, 2026, 14:57 SGT — Regular session

  • UOB shares up 0.22% at S$36.17 in afternoon trade
  • Bank bought back and cancelled 38,000 shares on Jan 12, a filing showed
  • Traders focus shifts to U.S. CPI later Tuesday and the Fed’s late-January meeting

United Overseas Bank (UOB) shares edged higher on Tuesday after the Singapore lender disclosed a fresh share buyback at the start of the week. UOB was up 0.22% at S$36.17 by 2:46 p.m. local time, while DBS Group rose 0.74% and OCBC gained 1.16%.

A filing showed UOB bought back 38,000 shares on Jan 12 for S$1.37 million, paying between S$36.02 and S$36.18 a share, and cancelled the stock. The bank has repurchased 19.05 million shares since the mandate began in April 2025, about 1.14% of its issued shares, the filing showed.

Buybacks matter more than the day-to-day price tick when rates are moving and investors are trying to handicap bank earnings in 2026. For lenders, net interest margin — the spread between what they earn on loans and what they pay on deposits — can swing with benchmarks, sometimes quickly.

In the U.S., several big brokers have pushed back their expected Federal Reserve rate cuts after the latest labour-market data, a shift that has fed through to global bond pricing. J.P. Morgan now expects the Fed’s next move to be a hike in 2027, while Goldman Sachs and Barclays delayed their cut calls into later 2026; J.P. Morgan said “the Fed could still ease later this year” if the data turn. Reuters

That makes Tuesday’s U.S. inflation report the next near-term tripwire for rate expectations. Economists in a Reuters survey forecast December CPI up 0.3% on the month and 2.7% on the year, and TD Securities’ chief U.S. macro strategist Oscar Munoz said the report should show “meaningful payback” after collection distortions tied to the government shutdown. Reuters

At home, OCBC’s head of equity research Carmen Lee pointed to “inflation, US Federal Reserve policy and interest rates” as key drivers for market direction as investors reposition early in the year. The Business Times

Still, buybacks don’t erase the bigger debate around bank margins and credit. UOB has flagged lower 2026 net interest margins after a sharp third-quarter profit fall that was hit by a jump in credit provisions, underscoring the risk that earnings momentum cools even if capital returns stay supportive.

The downside case is straightforward: a hotter inflation print, sticky funding costs, or another bump in credit quality could swamp the signalling value of small daily repurchases. In that kind of tape, buybacks become background noise.

The next catalyst lands later Tuesday with the U.S. CPI release at 8:30 a.m. ET, followed by the Fed’s Jan. 27-28 policy meeting — two dates investors are using to map the rate path that feeds into bank stocks.

Stock Market Today

  • Oracle Shares Dip Ahead of Critical AI-Focused Earnings Report
    June 9, 2026, 7:13 PM EDT. Oracle shares fell 2.84% to $205.81 on Tuesday ahead of its fiscal Q4 earnings report scheduled for Wednesday after market close. Investors are closely watching Oracle's AI-cloud infrastructure growth, margins, and backlog conversion into revenue amid concerns about debt and data-center delays. The company targets 19-21% sales growth and 46-50% cloud revenue increase this quarter, with a 2027 revenue forecast of $90 billion. Analyst price targets have risen, with BofA upgrading to $240, reflecting optimism on cloud segment expansion and AI opportunities. However, broader tech sell-off and AI data-center build delays are weighing on sentiment, while options markets imply potential share swings of up to 11% this week.

Latest articles

Casey’s climbs late as pizza and fuel beat Street

Casey’s climbs late as pizza and fuel beat Street

10 June 2026
Casey’s shares jumped nearly 3% after hours as the company smashed Wall Street’s profit and revenue forecasts, fueled by record earnings, strong pizza and fuel sales, a 14% dividend hike, and a $1 billion buyback expansion, making its S&P 500 debut a standout despite flat fuel volume guidance for 2027.
Oracle shares fall ahead of looming AI earnings test

Oracle shares fall ahead of looming AI earnings test

10 June 2026
Oracle shares slid 2.84% to $205.81 ahead of Wednesday’s earnings, as investors brace for proof that its costly AI-cloud buildout can deliver; options pricing signals potential 11% stock swing, with focus on cloud capacity, margins, and spending after Oracle’s own high growth guidance and recent data-center delay concerns.
Xcel Brands Pops on Coco Rocha-Baggallini News; Small Float Triggers Move

Xcel Brands Pops on Coco Rocha-Baggallini News; Small Float Triggers Move

10 June 2026
Xcel Brands soared 10.5% to $2.10 on record volume after announcing an exclusive Baggallini-Coco Rocha handbag deal, despite reporting a $2.5 million Q1 net loss and just $0.2 million in cash; with under 4 million shares in its float and potential for future stock dilution, investors face both sharp price swings and ongoing financial risks.
D-Wave Quantum Drops Almost 9% As QBTS Grabs Attention Again

D-Wave Quantum Drops Almost 9% As QBTS Grabs Attention Again

10 June 2026
D-Wave Quantum plunged 8.94% to $23.52 as investors dumped speculative tech stocks ahead of key inflation data, despite the company touting a 1,994% surge in Q1 bookings and a potential $100 million federal award that is not yet finalized; revenue fell 81% and D-Wave posted an $18.4 million net loss, with rivals IonQ, Rigetti, and Quantum Computing Inc. also down about 9–10%.
Ford AI, energy gains pause after rally

Ford AI, energy gains pause after rally

10 June 2026
Ford shares dipped to $14.95 in late trading as investors weighed GM’s new sodium-ion battery partnership against Ford’s own $17 billion energy-storage rally, with May sales down 13.6% and EDF deliveries not expected until 2028, leaving the stock’s future tied to contracting momentum and regulatory advantages.
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows
Previous Story

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop